Hanmi Pharm Signs Supply Contract for 3 Cardiovascular/Respiratory Drugs in Philippines and Malaysia (Approx. 52.7 Billion KRW)
-
Contract value: 52,738,853,215 KRW (3.4% of 2025 consolidated revenue)
-
Subject: 3 cardiovascular/respiratory drugs, Counterparty: Organon International GmbH
-
Territory: Philippines and Malaysia, Contract period: 10 years from local launch (expected 2026-2036)
-
Terms: Includes license fee of USD 1,075,000 and estimated 10-year sales of USD 34,088,924
-
Unapproved products may be excluded from supply scope if local approvals fail
KOSPI Filing Information
-
Filing: Conclusion of a Single Sales and Supply Contract
-
Company: Hanmi Pharm (128940)
-
Submission: Hanmi Pharm. Co., Ltd.
-
Receipt: 05-21-2026
-
Under KRX KOSPI Market Division